Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Recruiting · NCT07079735 · Interventional (participants receive a specific treatment) · Lead sponsor: Columbia University
View the official record on ClinicalTrials.gov →Interventions studied
LetermovirValganciclovir
What this trial is about
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Who can take part
Age range
18 Years to 99 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2, Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.
Exclusion criteria
- History of or suspected CMV disease within 6 months prior is excluded.
Where it is running
2 locations listed across 1 US state.
- NYP-Weill Cornell - New York, New York, United States
- Columbia University/NYP Milstein Hospital - New York, New York, United States